Ac-SSO110 has now received FDA orphan drug designation and investigational new drug application clearance for the treatment ...

Am J Health Syst Pharm. 2006;63(11):1022-1028. Q: How can potential medication errors be minimized when dispensing investigational drugs to better ensure patient safety and improve adherence to ...

Enrolment in this trial is expected to continue through the first quarter of 2025. Satellos is on track to submit a Phase II investigational new drug (IND) filing by the end of th ...

NORWOOD, Mass. - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), a $119 million market cap biopharmaceutical company, announced the release of an abstract detailing its Phase 1 clinical study of ...

The trial will evaluate the safety and effectiveness of a next-generation vaccine administered through a nasal spray or ...

MaxCyte's technology will support TG Therapeutics' efforts to develop a CD19 CAR T cell therapy program for autoimmune diseases.

Announced that topline data from the monotherapy Phase 3 VERITAC-2 trial isanticipated in 1Q25 –– Presented Phase 1b data from the TACTIVE-U ...

Topline data from FIBRONEER™-ILD show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change ...

The FDA has granted Fast Track Designation to Lundbeck's investigational drug, amlenetug, a potential new treatment option targeting Multiple System Atrophy (MSA).

A clinical trial supported by the National Institutes of Health (NIH) is testing an experimental treatment designed to help people suffering the effects of dengue, a mosquito-borne viral disease.

Revenue was $263.4 million and $59.2 million for the year and quarter ended December 31, 2024, respectively, compared with ...

Researchers at the LKS Faculty of Medicine of the University of Hong Kong (HKUMed) have invented an oral formulation of ...